Akalin He

OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa.

Pseudomonas aeruginosa 455, isolated in Ankara, Turkey, produced a pI 6.2 beta-lactamase determined by plasmid pMLH53 and resisted all beta-lactams except carbapenems. This beta-lactamase, named OXA-14, corresponded to OXA-10 (PSE-2) except that aspartate replaced glycine at position 157 and thus is intermediate between OXA-10 and OXA-11, which has aspartate at position 157 and a further substitution at position 143.

Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin.

Quinolones have been reported to be active against Brucella species in vitro. In this prospective randomized study, the efficacy and safety of the combination of ofloxacin plus rifampin were compared with the efficacy and safety of doxycycline plus rifampin, both combinations administered for a 6-week period in treatment of brucellosis. Sixty-one patients were enrolled in the study, and 49 had blood or bone marrow cultures positive for Brucella melitensis. Thirty patients received 200 mg of doxycycline plus 600 mg of rifampin once daily, and 31 patients were treated with 400 mg of ofloxacin plus 600 mg of rifampin once daily for 6 weeks. Nine patients in each group had complications of the disease. There was one therapeutic failure in the ofloxacin-rifampin treatment group, and one patient from each group relapsed (3.3% of those in the doxycycline-rifampin treatment group versus 3.2% of those in the ofloxacin-rifampin treatment group). Gastric discomfort was the major side effect observed in 13 patients (43.3%) who received doxycycline plus rifampin, whereas only 2 patients (6.5%) treated with ofloxacin plus rifampin complained of gastric irritation. These results suggest that the combination of ofloxacin plus rifampin administered for 6 weeks is as effective as doxycycline plus rifampin given for the same period, regardless of the presence of complications of the disease.

A retrospective review of 228 episodes of infective endocarditis where rheumatic valvular disease is still common

Two hundred and twenty-eight episodes of infective endocarditis in adult patients (mean age 36 years) were reviewed retrospectively. There were 183 episodes (80%) of native valve, 15 (7%) early prosthetic valve and 30 (13%) late prosthetic valve endocarditis. The most common predisposing factor was rheumatic valvular disease (65%). None of the patients were intravenous drug users. According to the Duke criteria, the number of definite, probable and rejected episodes were 121 (53%), 94 (41%) and 13 (6%), respectively. Additional minor criteria increased the number of definite endocarditis to 82%. The Duke criteria are not primarily intended to influence treatment decisions but are helpful in standardising research activities. The choice of the level of sensitivity or specificity of the criteria may be adjusted according to the aim of the study and prevalence of disease in a particular area. More sensitive criteria may be valuable in those countries where the prevalence of rheumatic valvular disease is still high.

Treatment of intracranial abscesses : experience with sulbactam/ampicillin

In an open prospective study, the efficacy of sulbactam/ampicillin (50 and 100 mg/kg, respectively, qid) was evaluated in 21 patients with intracranial abscess(es). Sixteen patients had cerebral, 3 epidural, and 2 cerebellar abscesses. Multiple lesions were found in 7 patients. Sixteen patients underwent surgical intervention, others were treated with antibiotic alone. The mean duration of antibiotic therapy (+/- SD) was 48 +/- 10 days (range 26-65 days). The mean duration of follow-up after completion of therapy (+/- SD) was 6 +/- 2.4 months. All patients had at least some reduction in size of abscess(es) within 3 weeks of the initiation of therapy as monitored by computerized tomography. Seventeen patients were cured, three patients died due to causes unrelated to their infection. One patient was reoperated since no clear improvement either clinically or radiologically was observed 18 days after the first operation. Side effects of sulbactam/ampicillin were minor and transient. Results obtained in this study indicate that sulbactam/ampicillin can be used in the treatment of intracranial abscesses, alone or with surgical intervention.

Septic shock as a predictor of mortality in bacteremia caused by coagulase-negative staphylococci.

Fifty episodes of bacteremia caused by coagulase-negative staphylococci at Hacettepe University Hospital over a five-year period were reviewed to evaluate the factors influencing the prognosis. Overall mortality and mortality due to bacteremia were 36% and 24%, respectively. Septic shock was determined to be the only factor adversely influencing mortality in both univariate and multivariate analyses. Age, sex, duration of hospitalization, origin of infection, underlying disease, presence of central intravascular or urinary catheters, and prior antibiotic therapy were not statistically significant parameters in predicting septic shock.

Long-Term Oral Ciprofloxacin in the Treatment of Prosthetic Valve Endocarditis due to Pseudomonas Aeruginosa

Prosthetic valve endocarditis caused by Pseudomonas aeruginosa is refractory to medical treatment alone and early valve replacement is necessary. We describe a 40-year-old patient in whom endocarditis developed in the early postoperative period, and reoperation was not considered feasible. Ciprofloxacin was administered orally in order to suppress bacteremia for 36 months. Long-term oral ciprofloxacin may provide an opportunity in the treatment of prosthetic valve endocarditis caused by Ps. aeruginosa in patients who are unfavorable candidates for reoperation.

Resistance patterns in Turkey

Resistance to antimicrobial agents in Gram-positive and Gram-negative bacteria is common in Turkey. In this review, resistance to several antimicrobial agents in this country is discussed for bacteria which have gained clinical importance in recent years. Among Gram-positives, staphylococci are of major importance because of their high level of resistance to many agents in the hospital and the community. Methicillin resistance in different hospitals ranges from 13% to 37%. High-level resistance to gentamicin occur in enterococci and resistance to glycopeptides have not been reported in these isolates. S. pneumoniae resistance to penicillin have been observed in Turkey as 47% in Hacettepe University and most of the resistant isolates were from children with severe underlying diseases. In reports from other hospitals, the level of resistance was lower because of a different patient population. In Gram-negative bacilli, aminoglycoside resistance is a significant problem in the treatment of severe infections in our country. The most common mechanism of resistance in our isolates is the plasmid-mediated enzymatic modification of these agents. Extended-broad spectrum beta-lactamases have been detected in Klebsiella spp. and Salmonella spp. in Turkey. In a Pseudomonas strain, an extended-spectrum variant of OXA-10 was identified. Some isolates were also shown to produce plasmid mediated PER-1 enzymes. Due to resistance problems encountered in many hospitals, restriction control measures have been started in some hospitals in order to limit the antibiotic use and our hope is the country-wide application of these precautions as soon as possible.

Atypical pneumonias: therapeutic possibilities

The atypical pneumonia syndrome is characterized by systemic complaints rather than respiratory symptoms. The causative pathogens include Mycoplasma, Chlamydia, Legionella and respiratory viruses (influenza, adenovirus, respiratory syncytial virus). The reported incidence of disease caused by these pathogens in community-acquired pneumonias varies from study to study. As most of these pathogens are intracellular, the antibiotics used in the treatment of atypical pneumonia are those able to penetrate into cells. Empirical antimicrobial therapy consists of macrolides (erythromycin or some of the newer agents such as roxithromycin, azithromycin or clarithromycin) or tetracyclines (e.g. doxycycline). In cases of severe legionellosis and in immunocompromised and critically-ill patients, the macrolides are sometimes given in combination with rifampicin. Promising alternatives are some of the newer fluoroquinolones (e.g. ofloxacin, pefloxacin) in the treatment of legionellosis.